Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 22, 2012 17:00 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals Highlights Mechanistic Features of Plecanatide, a Novel Investigational Drug for Chronic Idiopathic Constipation

NEW YORK, Oct. 22, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced the preclinical...
October 22, 2012 06:00 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals Initiates Dosing of Healthy Volunteers in Phase I Trial of SP-333, a Second-Generation GC-C Agonist to Treat Ulcerative Colitis

NEW YORK, Oct. 22, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders announced today that on October 19, 2012 the...
September 12, 2012 08:39 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals Files IND for SP-333, a Developmental Drug for Gastrointestinal Diseases

NEW YORK, Sept. 12, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that an...
August 23, 2012 16:45 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals Acquires FV-100 Shingles Drug From Bristol-Myers Squibb Company

NEW YORK, Aug. 23, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that it has signed an...
August 14, 2012 05:00 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals, Inc. Completes Screening and Planned Enrollment in Phase IIb/III Study in Chronic Idiopathic Constipation Patients

NEW YORK, Aug. 14, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders announced today that its Phase IIb/III plecanatide...
August 09, 2012 07:00 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals to Present at Canaccord Genuity 32nd Annual Growth Conference

NEW YORK, Aug. 9, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that its President...
July 20, 2012 18:13 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals Signs Definitive Agreement to Acquire Callisto Pharmaceuticals

NEW YORK, July 20, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP) and Callisto Pharmaceuticals, Inc. (OTCBB:CLSP) announced today that they have entered into a definitive merger...
June 25, 2012 09:15 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals Added to the Russell 3000(R), Russell Global, and Russell Microcap Indexes

NEW YORK, June 25, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP) (Nasdaq:SGYPU) (Nasdaq:SGYPW), a developer of new drugs to treat gastrointestinal disorders and diseases, today...
June 13, 2012 09:15 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals to Present at 2012 BIO International Convention

NEW YORK, June 13, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYPD) (Nasdaq:SGYPU) (Nasdaq:SGYPW), a developer of new drugs to treat gastrointestinal disorders and diseases, today...
June 06, 2012 12:53 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals Announces Exercise of Remainder of Over-Allotment Option by Aegis Capital Corp. Bringing Total Gross Proceeds to $51.75 Million

NEW YORK, June 6, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced the exercise of the...